约印医疗基金顾问委员会主席姒亭佑：医疗投资需要保持耐心

Group 1 - The "2025 Financial Annual Conference" held in Beijing focused on high-quality development of listed companies, emphasizing resilience and growth through cycles, with participation from over 200 listed companies and various industry leaders [1] - The "Golden Intelligence Award" recognized over 140 companies, including Haier Smart Home and Dongpeng Beverage, from more than 8,000 A-share, Hong Kong stock, and Chinese concept stock companies, highlighting their exemplary high-quality development [1] - A roundtable discussion on "New Era of Medicine" addressed key industry trends, including the localization of high-end medical equipment and global development paths, featuring insights from industry leaders and investment representatives [1] Group 2 - The development of the medical industry is an evolving process, with no definitive "best opportunity," and investments should be made with a forward-looking approach rather than chasing trends [3] - The historical context of the domestic pharmaceutical market shows a shift from generics to a focus on innovation, with policy changes impacting company strategies and emphasizing the need to address unmet market demands [3] - Future development directions in the pharmaceutical industry include research on drug resistance, enhancing drug efficacy, improving medication safety, and increasing patient adherence [4] Group 3 - The Chinese pharmaceutical industry is transitioning towards independent innovation, moving away from imitation and rapid following, which has increased market competition risks [5] - Global pharmaceutical companies have established comprehensive innovation ecosystems, and Chinese companies are beginning to adopt similar models, enhancing their innovation capabilities and global market influence [5] - The collaboration models between domestic and international pharmaceutical companies are evolving, reflecting the continuous improvement of China's biopharmaceutical innovation capacity [5] Group 4 - The pace of development in the medical industry remains constant, with changes occurring in market participants and innovation models across different stages [6]